At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Value of Mifepristone in Eliminating the Need for a Second Set of Osmotic Dilators Prior to Dilation and Evacuation Between 19-24 Weeks: A Randomized Trial
In Brief
A clinical study evaluating Mifepristone, Hygroscopic cervical dilators, and 2 other interventions for Abortion, Induced. Completed, enrolled 50 participants across 2 sites.
Detailed Summary
A common practice for preparation for surgical abortion after 19 weeks gestation is the placement of multiple sets of osmostic dilators 1-2 days prior to the procedure. The investigators aim to study the addition of mifepristone as an adjunct to cervical dilation prior to abortion between 19-24 weeks gestation, and its potential to minimize the number of painful procedures and time in clinic (or away from work/home) that multiple sets of dilators can require. The investigators hypothesize that one set of dilators with mifepristone will result in similar procedure times and decreased "total" time as two sets of dilators.
Study Details
Timeline
Interventions
200mg Mifepristone orally
Dilapan-S osmostic cervical dilators inserted through the internal os
400mcg buccal misoprostol 90 minutes pre-op
1mg digoxin administered intra-amniotically \~24 hours pre-op